Oral Apixaban for the Treatment of Acute Venous Thromboembolism

20132,256 citationsJournal Articlebronze Open Access

Authors

Giancarlo Agnelli · University of Perugia

Harry R. Büller · Academic Medical Center

Alexander T. Cohen · King's College Hospital

Madelyn Curto · Pfizer (United States)

Alexander Gallus · Flinders Medical Centre

Margot Johnson · Pfizer (United States)

Urszula Masiukiewicz ·

Abstract

A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Diagnosis and Treatment of Venous Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 9, pp. 799-808

DOI: 10.1056/nejmoa1302507

Field-Weighted Citation Impact: 158.53